Aural Analytics
1 known investors
Aural Analytics develops a cloud-based, mobile-first speech analytics platform that extracts clinical neuro-biomarkers from the speech signal to monitor brain health non-invasively. It provides clinical decision makers at health systems and pharmaceutical companies with objective measures of patients' neurological health, deployed in 8 languages across 4 continents.
Investors Β· 1
Non-dilutive funding Β· 5 SBIR/STTR awards
Federal grants β no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $1.4M |
| National Science Foundation | Phase ISTTR | 2021 | $256K |
| National Science Foundation | Phase II | 2019 | $750K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $224.9K |
| National Science Foundation | Phase I | 2017 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts β non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Aural Analytics do?
- Aural Analytics develops a cloud-based, mobile-first speech analytics platform that extracts clinical neuro-biomarkers from the speech signal to monitor brain health non-invasively. It provides clinical decision makers at health systems and pharmaceutical companies with objective measures of patients' neurological health, deployed in 8 languages across 4 continents.
- Who are Aural Analytics's investors?
- Aural Analytics's investors include Tamarisc Ventures.